Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Monatsschrift Kinderheilkunde
Erschienen in: Monatsschrift Kinderheilkunde 6/2007

01.06.2007 | Konsensuspapiere

Botulinumtoxin für Kinder mit Zerebralparesen: 10-Punkte-Tabelle, 2007

Ein interdisziplinärer deutscher Konsensus

verfasst von: Gesellschaft für Neuropädiatrie (GNP), Arbeitsgemeinschaft der niedergelassenen Neuropädiater (AG-NNP), Deutsche Gesellschaft für Sozialpädiatrie und Jugendmedizin (DGSPJ), Arbeitskreis Infantile Cerebralparesen der Deutschen Gesellschaft für Orthopädie und Orthopädische Chirurgie (DGOOC), Deutsche Gesellschaft für Neurologische Rehabilitation (DGNR), Deutschsprachige Vereinigung für Kinderorthopädie, Arbeitskreis Botulinumtoxin der Deutschen Gesellschaft für Neurologie (AK-BoNT der DGN)

Erschienen in: Monatsschrift Kinderheilkunde | Ausgabe 6/2007

Einloggen, um Zugang zu erhalten

Auszug

Florian Heinen1a, Leo Döderlein6d, Ulf Hustedt4c, Urban Fietzek2e, Steffen Berweck1a, Sebastian Schröder1a, Volker Mall5a, Bernd Wiedenhöfer6d, Andreas Sprinz8b, Reiner Benecke10g, Kell-Eyvind Behrens9f, Jörg Wissel7e, Ingeborg Krägeloh-Mann3a und die Teilnehmer des ZEBRA-Treffens (ZEBRA: Zielgerichteter Erwerb der Fähigkeiten zur Anwendung von Botulinumtoxin im Rahmen der neuropädiatrischen Ausbildung) im Dezember 2006 in München für:
a)
Gesellschaft für Neuropädiatrie (GNP) und stellvertretend für die Koautoren der europäischen Vorlage**
 
b)
Arbeitsgemeinschaft der niedergelassenen Neuropädiater (AG-NNP)
 
c)
Deutsche Gesellschaft für Sozialpädiatrie und Jugendmedizin (DGSPJ)
 
d)
Arbeitskreis infantile Cerebralparesen der Deutschen Gesellschaft für Orthopädie und Orthopädische Chirurgie (DGOOC)
 
e)
Deutsche Gesellschaft für Neurologische Rehabilitation (DGNR)
 
f)
Deutschsprachige Vereinigung für Kinderorthopädie
 
g)
Arbeitskreis Botulinumtoxin der Deutschen Gesellschaft für Neurologie (AK-BoNT der DGN)
 
…
Literatur
1.
Ackman JD, Russman BS, Thomas SS et al. (2005) Comparing botulinum toxin A with casting for treatment of dynamic equinus in children with cerebral palsy. Dev Med Child Neurol 47: 620–627CrossRefPubMed
2.
Ade-Hall RA, Moore AP (2000) Botulinum toxin type A in the treatment of lower limb spasticity in cerebral palsy. Cochrane Database Syst Rev 2: CD001408PubMed
3.
Allington NJ, Leroy N, Doneux C (2002) Ankle joint range of motion measurements in spastic cerebral palsy children: intraobserver and interobserver reliability and reproducibility of goniometry and visual estimation. J Pediatr Orthop B 11: 236–239CrossRefPubMed
4.
Anonymos (2000) Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Surveillance of Cerebral Palsy in Europe (SCPE). Dev Med Child Neurol 42: 816–824PubMed
5.
Anonymos (2007) The definition and classification of cerebral palsy. Dev Med Child Neurol 49: 1–44
6.
Aoki KR (2001) A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 39: 1815–1820CrossRefPubMed
7.
Ashwal S, Russman BS, Blasco PA et al. (2004) Practice parameter: diagnostic assessment of the child with cerebral palsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 62: 851–863PubMed
8.
Autti-Ramo I, Larsen A, Taimo A et al. (2001) Management of the upper limb with botulinum toxin type A in children with spastic type cerebral palsy and acquired brain injury: clinical implications. Eur J Neurol [Suppl 5] 8: 136–144
9.
Autti-Ramo I, Anttila H, Makela M (2007) Are current practices in the treatment of children with cerebral palsy research-based? Dev Med Child Neurol 49: 155–156PubMed
10.
Baker R, Jasinski M, Maciag-Tymecka I et al. (2002) Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol 44: 666–675CrossRefPubMed
11.
Bakheit AM, Bower E, Cosgrove A et al. (2001) Opinion statement on the minimal acceptable standards of healthcare in cerebral palsy. Disabil Rehabil 23: 578–582CrossRefPubMed
12.
Bakheit AM, Severa S, Cosgrove A et al. (2001) Safety profile and efficacy of botulinum toxin A (Dysport) in children with muscle spasticity. Dev Med Child Neurol 43: 234–238CrossRefPubMed
13.
Balkrishnan R, Camacho FT, Smith BP et al. (2002) Cost impact of botulinum toxin use in Medicaid-enrolled children with cerebral palsy. J South Orthop Assoc 11: 71–79PubMed
14.
Balkrishnan R, Naughton M, Smith BP et al. (2002) Parent caregiver-related predictors of health care service utilization by children with cerebral palsy enrolled in Medicaid. J Pediatr Health Care 16: 73–78PubMed
15.
Balkrishnan R, Manuel JC, Smith BP et al. (2004) Longitudinal examination of health outcomes associated with botulinum toxin use in children with cerebral palsy. J Surg Orthop Adv 13: 76–80PubMed
16.
Barbano RL (2001) Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is useful. Muscle Nerve 24: 1567–1568CrossRefPubMed
17.
Barwood S, Baillieu C, Boyd R et al. (2000) Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial. Dev Med Child Neurol 42: 116–121CrossRefPubMed
18.
Bax M, Goldstein M, Rosenbaum P et al. (2005) Proposed definition and classification of cerebral palsy, April 2005. Dev Med Child Neurol 47: 571–576CrossRefPubMed
19.
Beckung E, Hagberg G (2002) Neuroimpairments, activity limitations, and participation restrictions in children with cerebral palsy. Dev Med Child Neurol 44: 309–316CrossRefPubMed
20.
Berweck S, Feldkamp A, Francke A et al. (2002) Sonography-guided injection of botulinum toxin A in children with cerebral palsy. Neuropediatrics 33: 221–223CrossRefPubMed
21.
Berweck S, Heinen F (2006) Therapie der Cerebralparese mit Botulinumtoxin – Grundlagen, Praxis, Atlas, Blue Book, 2nd edn. Child & Brain GmbH, Bonn Berlin
22.
Berweck S, Schroeder AS, Fietzek UM et al. (2004) Sonography-guided injection of botulinum toxin in children with cerebral palsy. Lancet 363: 249–250CrossRefPubMed
23.
Berweck S, Schroeder AS, Lee SH et al. (2007) Secondary non-response due to antibody formation in a child after three injections of botulinum toxin B into the salivary glands. Dev Med Child Neurol 49: 62–64PubMedCrossRef
24.
Bjornson KF, McLaughlin JF (2001) The measurement of health-related quality of life (HRQL) in children with cerebral palsy. Eur J Neurol [Suppl 5] 8: 183–193
25.
Blasi J, Chapman E, Link E et al. (1993) Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP 25. Nature 365: 160–163CrossRefPubMedADS
26.
Bower E, McLellan DL (1994) Evaluating therapy in cerebral palsy. Child Care Health Dev 20: 409–419CrossRefPubMed
27.
Boyd RN, Graham HK (1999) Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy. Eur J Neurol [Suppl 4] 6: 23–35
28.
Boyd RN, Dobson F, Parrott J et al. (2001) The effect of botulinum toxin type A and a variable hip abduction orthosis on gross motor function: a randomized controlled trial. Eur J Neurol [Suppl 5] 8: 109–119
29.
Bucheler R, Schwab M, Morike K et al. (2002) Off label prescribing to children in primary care in Germany: retrospective cohort study. BMJ 324: 1311–1312CrossRefPubMed
30.
Cans C, Dolk H, Platt M et al. (2007) Recommendations from the SCPE collaboration group for defining and classifying cerebral palsy. Dev Med Child Neurol 109: 35–38
31.
Carr LJ, Cosgrove AP, Gringras P et al. (1998) Position paper on the use of botulinum toxin in cerebral palsy. UK Botulinum Toxin and Cerebral Palsy Working Party. Arch Dis Child 79: 271–273PubMed
32.
Chambers HG (2001) Treatment of functional limitations at the knee in ambulatory children with cerebral palsy. Eur J Neurol [Suppl 5] 8: 59–74
33.
Chin TY, Nattrass GR, Selber P et al. (2005) Accuracy of intramuscular injection of botulinum toxin A in juvenile cerebral palsy: a comparison between manual needle placement and placement guided by electrical stimulation. J Pediatr Orthop 25: 286–291CrossRefPubMed
34.
Conroy S, Choonara I, Impicciatore P et al. (2000) Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 320: 79–82CrossRefPubMed
35.
Corry IS, Cosgrove AP, Walsh EG et al. (1997) Botulinum toxin A in the hemiplegic upper limb: a double-blind trial. Dev Med Child Neurol 39: 185–193PubMedCrossRef
36.
Corry IS, Cosgrove AP, Duffy CM et al. (1998) Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. J Pediatr Orthop 18: 304–311CrossRefPubMed
37.
Cusick A, McIntyre S, Novak I et al. (2006) A comparison of goal attainment scaling and the Canadian Occupational Performance Measure for paediatric rehabilitation research. Pediatr Rehabil 9: 149–157CrossRefPubMed
38.
Damiano DL, Quinlivan JM, Owen BF et al. (2002) What does the Ashworth scale really measure and are instrumented measures more valid and precise? Dev Med Child Neurol 44: 112–118CrossRefPubMed
39.
Desloovere K, Molenaers G, Jonkers I et al. (2001) A randomized study of combined botulinum toxin type A and casting in the ambulant child with cerebral palsy using objective outcome measures. Eur J Neurol [Suppl 5] 8: 75–87
40.
Dong M, Yeh F, Tepp WH et al. (2006) SV2 is the protein receptor for botulinum neurotoxin A. Science 312: 592–596CrossRefPubMedADS
41.
Dressler D, Rothwell JC (2000) Electromyographic quantification of the paralysing effect of botulinum toxin in the sternocleidomastoid muscle. Eur Neurol 43: 13–16CrossRefPubMed
42.
Eames NW, Baker R, Hill N et al. (1999) The effect of botulinum toxin A on gastrocnemius length: magnitude and duration of response. Dev Med Child Neurol 41: 226–232CrossRefPubMed
43.
Eliasson AC, Krumlinde-Sundholm L, Shaw K et al. (2005) Effects of constraint-induced movement therapy in young children with hemiplegic cerebral palsy: an adapted model. Dev Med Child Neurol 47: 266–275CrossRefPubMed
44.
Eliasson AC, Rösblad B, Beckung E et al. (2005) Development and reliability of a system to classify hand function in children with cerebral palsy: Manual Ability Classification System (MACS). AACPDM, Orlando, FA
45.
Eliasson AC, Krumlinde-Sundholm L, Rosblad B et al. (2006) The Manual Ability Classification System (MACS) for children with cerebral palsy: scale development and evidence of validity and reliability. Dev Med Child Neurol 48: 549–554CrossRefPubMed
46.
Fehlings D, Rang M, Glazier J et al. (2000) An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr 137: 331–337CrossRefPubMed
47.
Feldman AB, Haley SM, Coryell J (1990) Concurrent and construct validity of the Pediatric Evaluation of Disability Inventory. Phys Ther 70: 602–610PubMed
48.
Flett PJ (2003) Rehabilitation of spasticity and related problems in childhood cerebral palsy. J Paediatr Child Health 39: 6–14CrossRefPubMed
49.
Flett PJ, Stern LM, Waddy H et al. (1999) Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy. J Paediatr Child Health 35: 71–77CrossRefPubMed
50.
Foran JR, Steinman S, Barash I et al. (2005) Structural and mechanical alterations in spastic skeletal muscle. Dev Med Child Neurol 47: 713–717CrossRefPubMed
51.
Fosang AL, Galea MP, McCoy AT et al. (2003) Measures of muscle and joint performance in the lower limb of children with cerebral palsy. Dev Med Child Neurol 45: 664–670CrossRefPubMed
52.
Frampton A, Browne GJ, Lam LT et al. (2003) Nurse administered relative analgesia using high concentration nitrous oxide to facilitate minor procedures in children in an emergency department. Emerg Med J 20: 410–413CrossRefPubMed
53.
Gormley ME Jr, Krach LE, Piccini L (2001) Spasticity management in the child with spastic quadriplegia. Eur J Neurol [Suppl 5] 8: 127–135
54.
Gracies JM (2004) Physiological effects of botulinum toxin in spasticity. Mov Disord [Suppl 8] 19: S120–128
55.
Graham HK, Selber P (2003) Musculoskeletal aspects of cerebral palsy. J Bone Joint Surg Br 85: 157–166CrossRefPubMed
56.
Graham HK, Aoki KR, Autti-Ramo et al. (2000) Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture 11: 67–79CrossRefPubMed
57.
Hagglund G, Andersson S, Duppe H et al. (2005) Prevention of severe contractures might replace multilevel surgery in cerebral palsy: results of a population-based health care programme and new techniques to reduce spasticity. J Pediatr Orthop B 14: 268–272
58.
Heinen F, Molenaers G, Fairhurst C et al. (2006) European consensus table 2006 on botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol 10: 215–225CrossRefPubMed
59.
Heinen F, Schroeder AS, Fietzek U et al. (2006) When it comes to botulinum toxin, children and adults are not the same: multimuscle option for children with cerebral palsy. Mov Disord 21: 2029–2030CrossRefPubMed
60.
Herrmann J, Geth K, Mall V et al. (2004) Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol 55: 732–735CrossRefPubMed
61.
Himmelmann K, Hagberg G, Beckung E et al. (2005) IX. Prevalence and origin in the birth-year period 1995–1998. Acta Paediatr 94: 287–294PubMedCrossRef
62.
Hoare BJ, Imms C (2004) Upper-limb injections of botulinum toxin-A in children with cerebral palsy: a critical review of the literature and clinical implications for occupational therapists. Am J Occup Ther 58: 389–397PubMedCrossRef
63.
Hoon AH, Johnston MV (2002) Cerebral palsy. In: Asbury AK, McKhann GM, McDonald WI et al. (eds) Diseases of the nervous system. Clinical neuroscience and therapeutic principles. Cambridge University Press, Cambridge, pp 568–580
64.
Houltram J, Noble I, Boyd RN et al.(2001) Botulinum toxin type A in the management of equinus in children with cerebral palsy: an evidence-based economic evaluation. Eur J Neurol [Suppl 5] 8: 194–202
65.
Ijzerman MJ, Nene AV (2002) Feasibility of the physiological cost index as an outcome measure for the assessment of energy expenditure during walking. Arch Phys Med Rehabil 83: 1777–1782CrossRefPubMed
66.
Jankovic J (2001) Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is rarely required. Muscle Nerve 24: 1568–1570CrossRefPubMed
67.
Jankovic J, Vuong KD, Ahsan J (2003) Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60: 1186–1188PubMed
68.
Jarvis S, Glinianaia SV, Torrioli MG et al. (2003) Cerebral palsy and intrauterine growth in single births: European collaborative study. Lancet 362: 1106–1111CrossRefPubMed
69.
Jefferson RJ (2004) Botulinum toxin in the management of cerebral palsy. Dev Med Child Neurol 46: 491–499CrossRefPubMed
70.
Kanagasundaram SA, Lane LJ, Cavalletto BP et al. (2001) Efficacy and safety of nitrous oxide in alleviating pain and anxiety during painful procedures. Arch Dis Child 84: 492–495CrossRefPubMed
71.
Kay RM, Rethlefsen SA, Fern-Buneo A et al. (2004) Botulinum toxin as an adjunct to serial casting treatment in children with cerebral palsy. J Bone Joint Surg Am 86-A: 2377–2384
72.
Keefer DJ, Tseh W, Caputo JL et al. (2004) Comparison of direct and indirect measures of walking energy expenditure in children with hemiplegic cerebral palsy. Dev Med Child Neurol 46: 320–324CrossRefPubMed
73.
Kennedy RM, Luhmann JD, Luhmann SJ (2004) Emergency department management of pain and anxiety related to orthopedic fracture care: a guide to analgesic techniques and procedural sedation in children. Paediatr Drugs 6: 11–31CrossRefPubMed
74.
Ketelaar M, Vermeer A, Helders PJ (1998) Functional motor abilities of children with cerebral palsy: a systematic literature review of assessment measures. Clin Rehabil 12: 369–380CrossRefPubMed
75.
King S, Teplicky R, King G et al. (2004) Family-centered service for children with cerebral palsy and their families: a review of the literature. Semin Pediatr Neurol 11: 78–86CrossRefPubMed
76.
Kinnett D (2004) Botulinum toxin A injections in children: technique and dosing issues. Am J Phys Med Rehabil 83: S59–64CrossRefPubMed
77.
Koman LA, Mooney JF, Smith BP et al. (2000) Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group. J Pediatr Orthop 20: 108–115CrossRefPubMed
78.
Koman LA, Brashear A, Rosenfeld S et al. (2001) Botulinum toxin type A neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics 108: 1062–1071CrossRefPubMed
79.
Koman LA, Paterson SB, Balkrishnan R (2003) Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin. PaediatrDrugs 5: 11–23
80.
81.
Krageloh-Mann I (2004) Imaging of early brain injury and cortical plasticity. Exp Neurol [Suppl 1] 190: S84–90
82.
Krageloh-Mann I (2005) Cerebral palsy: towards developmental neuroscience. Dev Med Child Neurol 47: 435CrossRefPubMed
83.
Krageloh-Mann I, Horber V (2007) The role of magnetic resonance imaging in elucidating the pathogenesis of cerebral palsy: a systematic review. Dev Med Child Neurol 49: 144–151PubMed
84.
Krageloh-Mann I, Hagberg G, Meisner C et al. (1994) Bilateral spastic cerebral palsy – a comparative study between southwest Germany and western Sweden. II: Epidemiology. Dev Med Child Neurol 36: 473–483PubMedCrossRef
85.
Lannin N, Scheinberg A, Clark K (2006) AACPDM systematic review of the effectiveness of therapy for children with cerebral palsy after botulinum toxin A injections. Dev Med Child Neurol 48: 533–539CrossRefPubMed
86.
Leach J (1997) Children undergoing treatment with botulinum toxin: the role of the physical therapist. Muscle Nerve Suppl 6: S194–207CrossRefPubMed
87.
Linder-Lucht M, Kirschner J, Herrmann J et al. (2006) Why do children with cerebral palsy discontinue therapy with botulinum toxin A? Dev Med Child Neurol 48: 319–320CrossRefPubMed
88.
Liptak GS, Accardo PJ (2004) Health and social outcomes of children with cerebral palsy. J Pediatr 145: S36–41CrossRefPubMed
89.
Love SC, Valentine JP, Blair EM et al. (2001) The effect of botulinum toxin type A on the functional ability of the child with spastic hemiplegia. An randomized controlled trial. Eur J Neurol [Suppl 5] 8: 50–58
90.
Lowe K, Novak I, Cusick A (2006) Low-dose/high-concentration localized botulinum toxin A improves upper limb movement and function in children with hemiplegic cerebral palsy. Dev Med Child Neurol 48: 170–175CrossRefPubMed
91.
Maathuis KG, Van der Schans CP, Van Iperen A et al. (2005) Gait in children with cerebral palsy: observer reliability of Physician Rating Scale and Edinburgh Visual Gait Analysis Interval Testing Scale. J Pediatr Orthop 25: 268–272CrossRefPubMed
92.
Mackey AH, Lobb GL, Walt SE et al. (2003) Reliability and validity of the Observational Gait Scale in children with spastic diplegia. Dev Med Child Neurol 45: 4–11PubMedCrossRef
93.
Mahrhold S, Rummel A, Bigalke H et al. (2006) The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Letters 580: 2011–2014CrossRefPubMed
94.
Majnemer A, Mazer B (2004) New directions in the outcome evaluation of children with cerebral palsy. Semin Pediatr Neurol 11: 11–17CrossRefPubMed
95.
Mall V, Heinen F, Kirschner J et al. (2000) Evaluation of botulinum toxin A therapy in children with adductor spasm by gross motor function measure. J Child Neurol 15: 214–217PubMed
96.
Mall V, Kirschner J, Linder M et al. (2003) Botulinum toxin A in children with cerebral palsy: evaluation of therapy with Pediatric Evaluation of Disability Inventory (PEDI). Pediatr Neurol 1: 29–34CrossRef
97.
Mall V, Heinen F, Siebel A et al. (2006) Treatment of adductor spasticity with BTX-A in children with CP: a randomized, double-blind, placebo-controlled study. Dev Med Child Neurol 48: 10–13CrossRefPubMed
98.
99.
Maloney FP, Mirrett P, Brooks C et al. (1978) Use of the Goal Attainment Scale in the treatment and ongoing evaluation of neurologically handicapped children. Am J Occup Ther 32: 505–510PubMed
100.
McCarthy ML, Silberstein CE, Atkins EA et al. (2002) Comparing reliability and validity of pediatric instruments for measuring health and well-being of children with spastic cerebral palsy. Dev Med Child Neurol 44: 468–476CrossRefPubMedMathSciNet
101.
McDowell BC, Hewitt V, Nurse A et al. (2000) The variability of goniometric measurements in ambulatory children with spastic cerebral palsy. Gait Posture 12: 114–121CrossRefPubMed
102.
Mohamed K, Moore AP, Rosenbloom L (2001) Adverse events following repeated injections with botulinum toxin A in children with spasticity. Dev Med Child Neurol 43: 791–792CrossRefPubMed
103.
Molenaers G, Eyssen M, Desloovere K et al. (1999) A multilevel approach to botulinum toxin type A treatment of the (ilio)psoas in spasticity in cerebral palsy. Eur J Neurol [Suppl 4] 6: 59–62
104.
Molenaers G, Desloovere K, Fabry G et al. (2006) The effects of quantitative gait assessment and botulinum toxin A on musculoskeletal surgery in children with cerebral palsy. J Bone Joint Surg Am 88: 161–170CrossRefPubMed
105.
Moore AP, Ade-Hall RA, McDowell M et al. (2001) Children with cerebral palsy tolerate repeated botulinum toxin injection sessions without general anaestethic. Mov Disord 16: 381CrossRef
106.
Naumann M, Jankovic J (2004) Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 20: 981–990CrossRefPubMed
107.
108.
Palisano RJ (1993) Validity of goal attainment scaling in infants with motor delays. Phys Ther 73: 651–658PubMed
109.
Palisano R, Rosenbaum PL, Walter S et al. (1997) Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 39: 214–223PubMedCrossRef
110.
Palisano RJ, Hanna SE, Rosenbaum PL et al. (2000) Validation of a model of gross motor function for children with cerebral palsy. Phys Ther 80: 974–985PubMed
111.
Palisano RJ, Cameron D, Rosenbaum PL et al. (2006) Stability of the gross motor function classification system. Dev Med Child Neurol 48: 424–428CrossRefPubMed
112.
Petruch U, Weber PM, Krageloh-Mann I, SCPE obot (2004) The reference and training manual of the SCPE (Surveillance of Cerebral Palsy in Europe). Neuropediatrics: 63
113.
Platt MJ, Cans C, Johnson A et al. (2007) Trends in cerebral palsy among infants of very low birth weight (<1500 g) or born prematurely (<32 weeks) in 16 European centres: a database study. Lancet 369: 43–50CrossRefPubMed
114.
Polak F, Morton R, Ward C et al. (2002) Double-blind comparison study of two doses of botulinum toxin A injected into calf muscles in children with hemiplegic cerebral palsy. Dev Med Child Neurol 44: 551–555CrossRefPubMed
115.
Radensky PW, Archer JW, Dournaux SF et al. (2001) The estimated cost of managing focal spasticity: a physician practice patterns survey. Neurorehabil Neural Repair 15: 57–68CrossRefPubMed
116.
Read HS, Hazlewood ME, Hillman SJ et al. (2003) Edinburgh visual gait score for use in cerebral palsy. J Pediatr Orthop 23: 296–301CrossRefPubMed
117.
Reddihough DS, King JA, Coleman GJ et al. (2002) Functional outcome of botulinum toxin A injections to the lower limbs in cerebral palsy. Dev Med Child Neurol 44: 820–827CrossRefPubMed
118.
Rodda J, Graham HK (2001) Classification of gait patterns in spastic hemiplegia and spastic diplegia: a basis for a management algorithm. Eur J Neurol [Suppl 5] 8: 98–108
119.
Rosales RL, Bigalke H, Dressler D (2006) Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol [Suppl 1] 13: 2–10
120.
Rose J, Gamble JG, Lee J et al. (1991) The energy expenditure index: a method to quantitate and compare walking energy expenditure for children and adolescents. J Pediatr Orthop 11: 571–578PubMed
121.
Rosenbaum P, Stewart D (2004) The World Health Organization International Classification of Functioning, Disability, and Health: a model to guide clinical thinking, practice and research in the field of cerebral palsy. Semin Pediatr Neurol 11: 5–10CrossRefPubMed
122.
Sanger TD (2003) Pathophysiology of pediatric movement disorders. J Child Neurol [Suppl 1] 18: S9–24
123.
Sanger TD, Delgado MR, Gaebler-Spira D et al. (2003) Classification and definition of disorders causing hypertonia in childhood. Pediatrics 111: e89–97CrossRefPubMed
124.
Satila H, Kotamaki A, Koivikko M et al. (2006) Low- and high-dose botulinum toxin A treatment: a retrospective analysis. Pediatr Neurol 34: 285–290CrossRefPubMed
125.
Schiavo G, Benfenati F, Poulain B et al. (1992) Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin [see comments]. Nature 359: 832–835CrossRefPubMedADS
126.
Schmid MF, Robinson JP, DasGupta BR (1993) Direct visualization of botulinum neurotoxin-induced channels in phospholipid vesicles. Nature 364: 827–830CrossRefPubMedADS
127.
Schneider JW, Gurucharri LM, Gutierrez AL et al. (2001) Health-related quality of life and functional outcome measures for children with cerebral palsy. Dev Med Child Neurol 43: 601–608CrossRefPubMed
128.
Schroeder AS, Berweck S, Lee SH et al. (2006) Botulinum toxin treatment of children with cerebral palsy – a short review of different injection techniques. Neurotox Res 9: 189–196PubMedCrossRef
129.
Schwerin A, Berweck S, Fietzek UM et al. (2004) Botulinum toxin B treatment in children with spastic movement disorders: a pilot study. Pediatr Neurol 31: 109–113CrossRefPubMed
130.
SCPE (2002) Prevalence and characteristics of children with cerebral palsy in Europe. Dev Med Child Neurol 44: 633–640CrossRefPubMed
131.
Sheean GL (2001) Botulinum treatment of spasticity: why is it so difficult to show a functional benefit? Curr Opin Neurol 14: 771–776CrossRefPubMed
132.
Speth LA, Leffers P, Janssen-Potten YJ et al. (2005) Botulinum toxin A and upper limb functional skills in hemiparetic cerebral palsy: a randomized trial in children receiving intensive therapy. Dev Med Child Neurol 47: 468–473CrossRefPubMed
133.
Stanley FJ, Blair EM, Alberman E (2000) Cerebral palsies: epidemiology and causal pathways. MacKeith Press, London
134.
Steinlin M, Heinen F (2003) Stellungnahme der Gesellschaft für Neuropädiatrie. Therapeutischer Wert von Botulinumtoxin bei der Behandlung von Bewegungsstörungen mit Spastizität im Kindesalter. Neuropädiatr Klin Prax 4: 171
135.
Sutherland DH, Kaufman KR, Wyatt MP et al. (1999) Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture 10: 1–9CrossRefPubMed
136.
Tilton AH (2003) Injectable neuromuscular blockade in the treatment of spasticity and movement disorders. J Child Neurol [Suppl 1] 18: S50–66
137.
Tilton AH, Maria BL (2001) Consensus statement on pharmacotherapy for spasticity. J Child Neurol 16: 66–67PubMedADSCrossRef
138.
Ubhi T, Bhakta BB, Ives HL et al. (2000) Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy [In Process Citation]. Arch Dis Child 83: 481–487CrossRefPubMed
139.
140.
Wallen MA, O’Flaherty S J, Waugh MC (2004) Functional outcomes of intramuscular botulinum toxin type A in the upper limbs of children with cerebral palsy: a phase II trial. Arch Phys Med Rehabil 85: 192–200CrossRefPubMed
141.
Wasiak J, Hoare B, Wallen M (2004) Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy. Cochrane Database Syst Rev 2004: CD003469
142.
Wenger DR, Rang M (1993) The art and practice of children’s orthopedics. Raven Press, New York
143.
Westhoff B, Seller K, Wild A et al. (2003) Ultrasound-guided botulinum toxin injection technique for the iliopsoas muscle. Dev Med Child Neurol 45: 829–832CrossRefPubMed
144.
WHO (2003) Strategy for child and adolescent health and development. Executive Board of the WHO, 111th Session, New York
145.
Wissel J, Muller J, Dressnandt J et al. (2000) Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 20: 44–49CrossRefPubMed
146.
Wood E, Rosenbaum P (2000) The gross motor function classification system for cerebral palsy: a study of reliability and stability over time. Dev Med Child Neurol 42: 292–296CrossRefPubMed
147.
Zurcher AW, Molenaers G, Desloovere K et al. (2001) Kinematic and kinetic evaluation of the ankle after intramuscular injection of botulinum toxin A in children with cerebral palsy. Acta Orthop Belg 67: 475–480PubMed
Metadaten
Titel
Botulinumtoxin für Kinder mit Zerebralparesen: 10-Punkte-Tabelle, 2007
Ein interdisziplinärer deutscher Konsensus
verfasst von
Gesellschaft für Neuropädiatrie (GNP)
Arbeitsgemeinschaft der niedergelassenen Neuropädiater (AG-NNP)
Deutsche Gesellschaft für Sozialpädiatrie und Jugendmedizin (DGSPJ)
Arbeitskreis Infantile Cerebralparesen der Deutschen Gesellschaft für Orthopädie und Orthopädische Chirurgie (DGOOC)
Deutsche Gesellschaft für Neurologische Rehabilitation (DGNR)
Deutschsprachige Vereinigung für Kinderorthopädie
Arbeitskreis Botulinumtoxin der Deutschen Gesellschaft für Neurologie (AK-BoNT der DGN)
Publikationsdatum
01.06.2007
Verlag
Springer-Verlag
Erschienen in
Monatsschrift Kinderheilkunde / Ausgabe 6/2007
Print ISSN: 0026-9298
Elektronische ISSN: 1433-0474
DOI
https://doi.org/10.1007/s00112-007-1516-7

Weitere Artikel der Ausgabe 6/2007

Monatsschrift Kinderheilkunde 6/2007 Zur Ausgabe

Leitthema

Beiträge der klinischen Neurophysiologie zum Verständnis der Entwicklung des Gehirns

Einführung zum Thema

Entwicklungsneurologie

Originalien

Der Mohn-Test

Leitthema

Zerebralparesen

Leserforum

Neues Arzneimittelgesetz

Originalien

Pflegebedürftigkeit von Kindern und Jugendlichen nach SGB XI

Neu im Fachgebiet Pädiatrie

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

30.04.2024 Rhinitis und Sinusitis Nachrichten

Persistieren Sinusitisbeschwerden bei Kindern länger als zehn Tage, ist eine Antibiotikatherapie häufig gut wirksam: Ein Therapieversagen ist damit zu über 40% seltener zu beobachten als unter Placebo.

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

23.04.2024 Typ-1-Diabetes Nachrichten

Wenn Kinder an Werktagen zum Arzt gehen, werden neu auftretender Typ-1-Diabetes und diabetische Ketoazidosen häufiger erkannt als bei Arztbesuchen an Wochenenden oder Feiertagen.

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

22.04.2024 Fehlsichtigkeit Nachrichten

Augentropfen mit niedrig dosiertem Atropin können helfen, das Fortschreiten einer Kurzsichtigkeit bei Kindern zumindest zu verlangsamen, wie die Ergebnisse einer aktuellen Studie mit verschiedenen Dosierungen zeigen.

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

18.04.2024 Spinale Muskelatrophien Nachrichten

Seit 2021 ist die Untersuchung auf spinale Muskelatrophie Teil des Neugeborenen-Screenings in Deutschland. Eine Studie liefert weitere Evidenz für den Nutzen der Maßnahme.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise